#Sweden #Stockholm #Psoriasis #WHO Foundation #IFPA

Strategic Collaboration to Combat Psoriasis

On February 10, 2026, the International Federation of Psoriasis Associations (IFPA) and the WHO Foundation announced a significant multi-year collaboration aimed at enhancing care for individuals living with psoriasis. This partnership represents a pivotal step in the global fight against psoriasis and seeks to raise awareness and improve access to treatment for over 100 million affected individuals worldwide.

Understanding Psoriasis

Psoriasis is a chronic, non-contagious disease that primarily manifests on the skin but affects the entire body. It is closely linked with various serious health conditions, including depression, diabetes, obesity, and cardiovascular diseases. For many, psoriasis carries substantial physical, emotional, and economic burdens. Despite its vast implications, psoriasis remains one of the most misunderstood and overlooked diseases globally. According to the Global Psoriasis Atlas, only about 20% of countries maintain epidemiological data on psoriasis, hindering timely diagnosis and equal access to care.

Objectives of the Collaboration

The collaboration between IFPA and the WHO Foundation marks a crucial milestone in strengthening global health initiatives for psoriasis. The agreement focuses on enhancing evidence around the condition, updating knowledge and policy frameworks, and improving the accessibility of diagnosis and treatment. As Frida Dunger, IFPA's Executive Director, noted, "Signing this agreement with the WHO Foundation is a critical moment for IFPA and the global psoriasis community. We are eager to leverage WHO's leadership to create meaningful change for those living with psoriasis."

The partnership aims to address many urgent issues facing psoriasis patients, particularly in low- and middle-income countries. Statistics reveal that over 80% of people with psoriasis face stigma and discrimination; nearly half contend with anxiety while one in three avoid career opportunities due to their condition.

Greater Inclusion in Healthcare Systems

Anil Soni, CEO of the WHO Foundation, emphasized the importance of integrating skin health into broader health discussions: "Psoriasis exemplifies the intersection of dermatological health with other non-communicable diseases and mental health. By collaborating with IFPA, we hope to mobilize support and strengthen guidelines that improve access to care for psoriasis patients."

Key Focus Areas

Among the collaboration's key directives is the revision of the WHO's 2014 resolution on psoriasis and the 2016 Global Report on Psoriasis, which were groundbreaking documents that placed psoriasis on the global health agenda. Given that more than a decade has passed since these documents were published, an update is both necessary and urgent.

The IFPA and WHO will work together to revisit the Global Report on Psoriasis, incorporating new prevalence data, up-to-date scientific knowledge, and emerging treatment options.

Moreover, the partnership aims to:

• - Share evidence-based guidance and policy recommendations with member states.
• - Develop AI-based diagnostic tools for quicker and more accurate diagnoses, particularly in resource-limited settings.
• - Train healthcare professionals to ensure early recognition and effective treatment of psoriasis.

This initiative is set to elevate psoriasis within the larger global discourse on chronic illnesses and mental health, ensuring that those affected are included in both national and international health guidelines.

About IFPA

Founded in 1971 and headquartered in Stockholm, the IFPA serves as the global body advocating for the rights and better living conditions of those affected by psoriasis. With a membership representing over 60 million individuals worldwide, the organization focuses on global partnerships and campaigns that underscore the need for improved health systems and recognition of psoriasis as a serious health issue.

About WHO Foundation

Established in 2020, the WHO Foundation operates independently from its Geneva headquarters and aims to support the World Health Organization's mission. By mobilizing philanthropic capital and forging strategic partnerships, the foundation seeks to address urgent global health challenges while promoting equitable health access.

This collaborative effort between IFPA and the WHO Foundation signifies a concerted step towards better recognition and treatment of psoriasis, ultimately enhancing the quality of life for millions around the globe.